...
首页> 外文期刊>Expert opinion on therapeutic targets >New targets in the treatment of anorexia nervosa.
【24h】

New targets in the treatment of anorexia nervosa.

机译:治疗神经性厌食症的新目标。

获取原文
获取原文并翻译 | 示例
           

摘要

The pathophysiology of anorexia nervosa (AN) is complex and involves alterations of serotonin, dopamine and histamine neurotransmitters. In addition, receptor activity is disturbed, presumably in response to the neurotransmitter changes. These alterations are reviewed in relation to symptomatology and outcome of AN. Neuropeptide and peripheral orexigenic and satiety peptide research is in its infancy but holds much promise to shed light on the pathophysiological mechanisms involved in this illness. Current drug therapies have not demonstrated the efficacy desired in the treatment of AN. Current therapies are reviewed and new drug targets are explored. Compounds that interact with serotonin, histamine and dopamine receptors may offer unique treatment opportunities. In the future, the manipulation of peptides may add to the therapeutic potential of pharmacotherapy.
机译:神经性厌食症(AN)的病理生理很复杂,涉及5-羟色胺,多巴胺和组胺神经递质的改变。另外,大概是响应神经递质的变化,受体的活性受到干扰。这些改变与AN的症状和结局有关。神经肽和外周致病原和饱腹感肽的研究尚处于起步阶段,但很有希望阐明这种疾病的病理生理机制。当前的药物疗法尚未证明在AN的治疗中期望的功效。审查了当前的疗法,并探索了新的药物靶标。与血清素,组胺和多巴胺受体相互作用的化合物可能会提供独特的治疗机会。将来,肽的操作可能会增加药物疗法的治疗潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号